PFE Nov 2024 23.000 call
| Previous Close | 7.05 |
| Open | 7.15 |
| Bid | 6.95 |
| Ask | 7.05 |
| Strike | 23.00 |
| Expire Date | 2024-11-15 |
| Day's Range | 7.05 - 7.15 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 45 |
Investor's Business DailyIs Pfizer Stock A Buy Or A Sell On Its New Weight-Gain Approach?
Pfizer is now working on a new approach to weight, helping some patients gain weight. Is Pfizer stock a buy or a sell?
ZacksStudy: Merck and Daiichi's Lung Cancer Treatment Shows Promise
MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in previously treated EGFR-mutated NSCLC.
- Yahoo Finance Video
Weight loss drug pricing under fire with pills on the horizon
Senior health reporter Anjalee Khemlani joins Brad Smith and Madison Mills on Catalysts to take a look at pharmaceutical stocks like Novartis (NVS) and Novo Nordisk (NVO) as weight loss drug makers are set to meet with lawmakers like Senator Bernie Sanders to discuss pricing. Khemlani provides insight into the weight loss drug market and pricing in the US compared to other countries around the world. She explains that Pfizer (PFE), Eli Lilly (LLY), and Novo are among the candidates who could offer weight loss drugs in pill form rather than through injection, which could transform the market. For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Naomi Buchanan.
